PROPERTY, PLANT AND EQUIPMENT

12 Months Ended

Mar. 30, 2024

Property, Plant and Equipment [Abstract]

Property, plant and equipment consisted of the following:


(In thousands)	March 30, 2024		April 1, 2023
Land	$	4,130	$	5,358
Building and building improvements	124,338		127,634
Plant equipment and machinery	204,622		194,539
Office equipment and information technology	129,979		123,611
Haemonetics equipment	456,414		463,706
Construction in progress	39,694		29,367
Total	959,177		944,215
Less: accumulated depreciation	(647,815)		(633,330)
Property, plant and equipment, net	$	311,362	$	310,885

Depreciation expense was $55.8 million, $51.2 million and $44.4 million in fiscal 2024, 2023 and 2022, respectively.

In fiscal 2024, $5.8 million of the Company’s property, plant and equipment met held for sale accounting criteria and was reclassified to Prepaid expenses and other current assets in the consolidated balance sheets. In the first quarter of fiscal 2025, subsequent to the year ended March 30, 2024, the Company received $19.9 million in connection with the sale of the applicable facility.

During fiscal 2022, the Company incurred an impairment of property, plant and equipment of $5.2 million in connection with the 2020 Program, refer to Note 5 - Restructuring for details on the 2020 Program, and $2.8 million of accelerated depreciation costs related to disposables manufacturing equipment that was no longer in use. The impairment charge was included in cost of goods sold on the consolidated statements of income and impacted the Plasma reporting segment.